Medicis shares surge after settlement
The drugmaker says it cuts a deal to end a patent dispute over a generic version of the acne drug Solodyn.
 |
| The companies announced a settlement of the patent dispute over a generic version of the acne drug Solodyn. |
NEW YORK (CNNMoney.com) -- Shares of Medicis Pharmaceutical Corp. rose more than 25% in midday trading Tuesday, following the settlement of a patent dispute with a competitor.
Late Monday, Medicis (MRX) announced it cut a deal with Impax Laboratories Inc., ending a patent dispute over a generic version of the acne drug Solodyn.
At 12:30 p.m. ET, Medicis shares were up $2.81 to $13.93.
According to the announcement, Impax retains the right to market a generic version no later than November 2011. After launching its drug, the conpanies said Impax will pay Medicis a royalty based on sales.
The companies will also collaborate on research and development of five "strategic dermatology product opportunities," including a more advanced version of Solodyn, according to a statement issued by the companies.
The companies said Impax has agreed that Medicis' patents relating to Solodyn are valid and enforceable. 
-
The Becerras spoiled themselves with a puppy. Here's what 6 other readers are indulging on. More -
Santa is no part-time gig for these St. Nicks. Meet the hardest working Santas in the business. More -
More people can't afford their pets, and shelters struggle to keep up with the influx. Play -
The house on Hawaii's big island should fetch near $12 million. More -
Small automakers are beating the Big 3 in the race for sweet new rides. More -
Lauren Bush's FEED project lands her on Fortune's Most Powerful Women Entrepreneurs list. More -
Production is starting on the world's most luxe ocean liner: The Utopia. More
